Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer

Significant evidence has accumulated that DNA-methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene can serve as a prognostic and predictive biomarker in breast cancer. PITX2 DNA-methylation data have been obtained so far from microarray and polymerase chain reaction (PCR)-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Schricker, Gabriele, Napieralski, Rudolf, Noske, Aurelia, Piednoir, Elodie, Manner, Olivia, Schüren, Elisabeth, Lauber, Jürgen, Perkins, Jonathan, Magdolen, Viktor, Schmitt, Manfred, Ulm, Kurt, Weichert, Wilko, Kiechle, Marion, Martens, John W. M., Wilhelm, Olaf G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237923/
https://www.ncbi.nlm.nih.gov/pubmed/30442983
http://dx.doi.org/10.1038/s41598-018-34919-1
_version_ 1783371272373141504
author Schricker, Gabriele
Napieralski, Rudolf
Noske, Aurelia
Piednoir, Elodie
Manner, Olivia
Schüren, Elisabeth
Lauber, Jürgen
Perkins, Jonathan
Magdolen, Viktor
Schmitt, Manfred
Ulm, Kurt
Weichert, Wilko
Kiechle, Marion
Martens, John W. M.
Wilhelm, Olaf G.
author_facet Schricker, Gabriele
Napieralski, Rudolf
Noske, Aurelia
Piednoir, Elodie
Manner, Olivia
Schüren, Elisabeth
Lauber, Jürgen
Perkins, Jonathan
Magdolen, Viktor
Schmitt, Manfred
Ulm, Kurt
Weichert, Wilko
Kiechle, Marion
Martens, John W. M.
Wilhelm, Olaf G.
author_sort Schricker, Gabriele
collection PubMed
description Significant evidence has accumulated that DNA-methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene can serve as a prognostic and predictive biomarker in breast cancer. PITX2 DNA-methylation data have been obtained so far from microarray and polymerase chain reaction (PCR)-based research tests. The availability of an analytically validated in vitro methylation-specific real-time PCR assay format (therascreen PITX2 RGQ PCR assay) intended for the determination of the percent methylation ratio (PMR) in the (PITX2) promoter 2 prompted us to investigate whether the clinical performance of these different assay systems generate comparable clinical outcome data. Mathematically converted microarray data of a previous breast cancer study (n = 204) into PMR values leads to a PITX2 cut-off value at PMR 14.73. Recalculation of the data to experimentally equivalent PMRs with the PCR PITX2 assay leads to a cut-off value at PMR 12 with the highest statistical significance. This cut-off predicts outcome of high-risk breast cancer patients to adjuvant anthracycline-based chemotherapy (n = 204; Hazard Ratio 2.48; p < 0.001) comparable to microarray generated results (n = 204; Hazard ratio 2.32; p < 0.0001). The therascreen PITX2 RGQ PCR assay is an analytically validated test with high reliability and robustness and predicts outcome of high-risk breast cancer patients to anthracycline-based chemotherapy.
format Online
Article
Text
id pubmed-6237923
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62379232018-11-23 Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer Schricker, Gabriele Napieralski, Rudolf Noske, Aurelia Piednoir, Elodie Manner, Olivia Schüren, Elisabeth Lauber, Jürgen Perkins, Jonathan Magdolen, Viktor Schmitt, Manfred Ulm, Kurt Weichert, Wilko Kiechle, Marion Martens, John W. M. Wilhelm, Olaf G. Sci Rep Article Significant evidence has accumulated that DNA-methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene can serve as a prognostic and predictive biomarker in breast cancer. PITX2 DNA-methylation data have been obtained so far from microarray and polymerase chain reaction (PCR)-based research tests. The availability of an analytically validated in vitro methylation-specific real-time PCR assay format (therascreen PITX2 RGQ PCR assay) intended for the determination of the percent methylation ratio (PMR) in the (PITX2) promoter 2 prompted us to investigate whether the clinical performance of these different assay systems generate comparable clinical outcome data. Mathematically converted microarray data of a previous breast cancer study (n = 204) into PMR values leads to a PITX2 cut-off value at PMR 14.73. Recalculation of the data to experimentally equivalent PMRs with the PCR PITX2 assay leads to a cut-off value at PMR 12 with the highest statistical significance. This cut-off predicts outcome of high-risk breast cancer patients to adjuvant anthracycline-based chemotherapy (n = 204; Hazard Ratio 2.48; p < 0.001) comparable to microarray generated results (n = 204; Hazard ratio 2.32; p < 0.0001). The therascreen PITX2 RGQ PCR assay is an analytically validated test with high reliability and robustness and predicts outcome of high-risk breast cancer patients to anthracycline-based chemotherapy. Nature Publishing Group UK 2018-11-15 /pmc/articles/PMC6237923/ /pubmed/30442983 http://dx.doi.org/10.1038/s41598-018-34919-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Schricker, Gabriele
Napieralski, Rudolf
Noske, Aurelia
Piednoir, Elodie
Manner, Olivia
Schüren, Elisabeth
Lauber, Jürgen
Perkins, Jonathan
Magdolen, Viktor
Schmitt, Manfred
Ulm, Kurt
Weichert, Wilko
Kiechle, Marion
Martens, John W. M.
Wilhelm, Olaf G.
Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title_full Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title_fullStr Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title_full_unstemmed Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title_short Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer
title_sort clinical performance of an analytically validated assay in comparison to microarray technology to assess pitx2 dna-methylation in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237923/
https://www.ncbi.nlm.nih.gov/pubmed/30442983
http://dx.doi.org/10.1038/s41598-018-34919-1
work_keys_str_mv AT schrickergabriele clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT napieralskirudolf clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT noskeaurelia clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT piednoirelodie clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT mannerolivia clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT schurenelisabeth clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT lauberjurgen clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT perkinsjonathan clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT magdolenviktor clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT schmittmanfred clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT ulmkurt clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT weichertwilko clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT kiechlemarion clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT martensjohnwm clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer
AT wilhelmolafg clinicalperformanceofananalyticallyvalidatedassayincomparisontomicroarraytechnologytoassesspitx2dnamethylationinbreastcancer